Skip to main content
SpringerLink
Log in

Economic Assessment of the Secondary Prevention of Ischaemic Events with Lysine Acetylsalicylate

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective: to analyse the economic benefits, in comparison with placebo, of the secondary prevention of ischaemic stroke and myocardial infarction (MI) with lysine acetylsalicylate (Kardégic®) in patients with a history of ischaemic stroke, MI or stable and unstable angina pectoris.

Design and setting: This was a modelling study from the perspectives of direct medical costs, the social security system and society in France.

Methods: Efficacy data for the secondary prevention of ischaemic events were derived from the Antiplatelet Trialists’ Collaboration meta-analysis on antithrombotics. The rates and costs of ischaemic disease and of serious gastrointestinal adverse affects arising from long term aspirin treatment, as well as the costs of treatment with lysine acetylsalicylate, were taken from published sources, using French data where possible.

Results: From the social security perspective, the estimated cost-effectiveness ratios show that the prevention of MI in patients with a history of unstable angina (with a 1-year follow-up) is a cost-saving strategy, with net benefits ranging from $US5703 (1996 prices) per avoided MI for lysine acetylsalicylate 300 mg/day to $US5761 per avoided MI for lysine acetylsalicylate 75 mg/day. The prevention of MI and stroke is also a cost-saving strategy in patients with prior MI [net benefits in a 2-year follow-up (5% discount rate) ranging from $US15 to $US494 per avoided MI and from $US37 to $US1170 per avoided stroke]. This was also true in patients with prior ischaemic stroke (net benefits in a 3-year follow-up ranging from $US610 to $US2082 per avoided MI and from $US176 to $US599 per avoided stroke). Finally, a 4-year follow-up in patients with a history of stable angina pectoris shows that prophylactic treatment with lysine acetylsalicylate is associated with net costs per avoided MI, ranging from $US4375 to $US3608 per avoided event. Sensitivity analysis confirmed that prophylaxis with lysine acetylsalicylate in patients at high risk of cardiovascular and cerebrovascular events results in savings in social security expenditure.

Conclusions: Our results underline the high economic benefit of using lysine acetylsalicylate to prevent secondary ischaemic stroke and MI in patients at high risk of cardiovascular and/or cerebrovascular events, leading to savings for the social security system and society.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Table VII
Table VIII

Similar content being viewed by others

References

  1. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA1996; 276: 1409–15

  2. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20: 735–44

    Article  PubMed  CAS  Google Scholar 

  3. Henke CJ, Burchmore MJ. The economic impact of tacrine in the treatment of Alzheimer’s disease. Clin Ther 1997; 19: 330–45

    Article  PubMed  CAS  Google Scholar 

  4. Wimo A, Karlsson G, Nordberg A, et al. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord 1997; 11 (4): 191–200

    PubMed  CAS  Google Scholar 

  5. O’Brien BJ, Goeree R, Hux M, et al. Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. J Am Geriatr Soc 1999; 47 (5): 570–8

    PubMed  Google Scholar 

  6. Small GW, Donohue JA, Brooks RL. An economic evaluation of donepezil in the treatment of Alzheimer’s disease. Clin Ther 1998; 20 (4): 838–50

    Article  PubMed  CAS  Google Scholar 

  7. Fenn P, Gray A. Estimating long term cost savings from treatment of Alzheimer’s disease: a modelling approach. Pharmacoeconomics 1999; 16 (2): 165–74

    Article  PubMed  CAS  Google Scholar 

  8. Caro J, Klittich W, McGuire, et al. The West Of Scotland COronary Prevention Study: economic benefit analysis of primary prevention with pravastatin in WOSCOPS. BMJ 1997; 315: 1577–82

    Article  PubMed  CAS  Google Scholar 

  9. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996; 93: 1796–802

    Article  PubMed  CAS  Google Scholar 

  10. Johannesson M, Jöhnsson B, Kjekshus J, et al. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332–6

    Article  PubMed  CAS  Google Scholar 

  11. Van Bergen PFMM, Jonker JJC, van Hout BA, et al. Costs and effects of long-term oral anticoagulant treatment after MI. JAMA 1995; 273 (12): 925–8

    Article  PubMed  Google Scholar 

  12. Scott G, Scott HM. Application of the findings of the European Stroke Prevention Study 2 (ESPS-2) to a NewZealand ischaemic stroke cost analysis. Pharmacoeconomics 1997; 12: 667–74

    Article  PubMed  CAS  Google Scholar 

  13. Evers SMA, Engel GL, Ament AJH. Cost of stroke in The Netherlands from a societal perspective. Stroke 1997; 28: 1375–81

    Article  PubMed  CAS  Google Scholar 

  14. Russell MW, Huse DM, Drowns S, et al. Direct medical costs of coronary artery disease in the United States. Am J Cardiol 1998; 81: 1110–5

    Article  PubMed  CAS  Google Scholar 

  15. Sagmeister M, Gessner U, Oggier W, et al. An economic analysis of ischaemic heart disease in Switzerland. Eur Heart J 1997; 18: 1102–9

    Article  PubMed  CAS  Google Scholar 

  16. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, MI, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106

    Article  Google Scholar 

  17. GiroudM,Milan C, Beuriat P, et al. Incidence and survival rates during a two-year period, of intracerebral and subarachnoid haemorrhages, cortical infarcts, lacunes and transient ischaemic attacks: the stroke registry of Dijon. Int J Epidemiol 1991; 20: 892–9

  18. Federation Francaise de Cardiologie. Les registres français des cardiopathies ischémiques. L’infarctus du myocarde: données des trois registres des cardiopathies ischémiques de Lille, Strasbourg et Toulouse. Paris: Federation Francaise de Cardiologie, 1996

    Google Scholar 

  19. Murray CJL, Lopez AD. Global health statistics: WHO global burden of disease and injury series. Geneva: World Health Organization, 1996

    Google Scholar 

  20. Task Force of the European Society of Cardiology. Management of stable angina pectoris. Eur Heart J 1997; 18: 394–413

    Article  Google Scholar 

  21. Goldberg M, Leclerc A, editors. Cohorte GAZEL: 20 000 volontaires d’EDF-GDF pour la recherche médicale. Paris: Editions INSERM, Collection Grandes Enquêtes, 1994

    Google Scholar 

  22. RISC Group. Risk of MI and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30

    Article  Google Scholar 

  23. Wallentin LD, Research Group on Instability in Coronary Artery Disease in Southeast Sweden (RISC). Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for MI, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol 1991; 18: 1587–93

    Article  Google Scholar 

  24. Nyman I, Larsson H, Wallentin L, et al. Prevention of serious cardiac events by low-dose aspirin in patients with silent MI. Lancet 1992; 340: 497–501

    Article  PubMed  CAS  Google Scholar 

  25. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of MI in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421–5

    Article  PubMed  CAS  Google Scholar 

  26. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after MI. Circulation 1980; 62: 53–8

    Google Scholar 

  27. Elwood PC. Trial of acetylsalicylic acid in the secondary prevention of mortality from MI [letter]. BMJ 1981; 282: 481

    Article  PubMed  CAS  Google Scholar 

  28. Breddin K, Loew D, Lechner K, et al. Secondary prevention of MI: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis 1980; 9: 325–44

    PubMed  CAS  Google Scholar 

  29. Breddin K, Loew D, Lechner K, et al. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in the secondary prevention of MI. Circulation 1980; 62: 63–72

    Google Scholar 

  30. Coronary Drug Project (CDP) Research Group. The coronary drug project: design, methods and baseline results. Circulation 1973: 47 Suppl. 1: 1–49

    Article  Google Scholar 

  31. Coronary Drug Project (CDP) Research Group. Aspirin in coronary heart disease. J Chronic Dis 1976: 29: 625–42

    Article  Google Scholar 

  32. Coronary Drug Project (CDP) Research Group. Aspirin in coronary heart disease. Circulation 1980: 62 Suppl. 5: 59–62

    Google Scholar 

  33. Vogel G, Fischer C, Huyke R. Prevention of reinfarction with acetylsalicylic acid. In: Breddin K, Loew D, Uberla K, et al., editors. Prophylaxis of venous peripheral cardiac and cerebral vascular diseases with acetylsalicylic acid. Stuttgart: Shattauer, 1981: 123–8

    Google Scholar 

  34. Aspirin MI Study (AMIS) Research Group. AMIS: a randomized controlled trial of aspirin in persons recovered from MI. JAMA 1980; 243: 661–9

    Article  Google Scholar 

  35. Aspirin MI Study (AMIS) Research Group. AMIS: the aspirin MI study: final results. Circulation 1980; 62 Suppl. 5: 79–84

    Google Scholar 

  36. Fields WS, Lemak NA, Frankowski RF, et al. Controlled trial of aspirin in cerebral ischemia. Stroke 1977; 8: 301–14

    Article  PubMed  CAS  Google Scholar 

  37. Fields WS, Lemak NA, Frankowski RF, et al. Controlled trial of aspirin in cerebral ischemia. Pt II: surgical group. Stroke 1978; 9: 309–18

    Article  PubMed  CAS  Google Scholar 

  38. Lemak NA, Fields WS, Gary Jr HE. Controlled trial of aspirin in cerebral ischemia: an addendum. Neurology 1986; 36: 705–10

    Article  PubMed  CAS  Google Scholar 

  39. Boysen G, Soelberg-Sorensen P, Juhker M, et al. Danish very low- dose aspirin after carotid endarterectomy trial. Stroke 1988; 19: 1211–5

    Article  PubMed  CAS  Google Scholar 

  40. Reuther R, Dorndorf W. Aspirin in patients with cerebral ischemia and normal angiograms or non-surgical lesions. In: Breddin K, Dorndorf W, Loew D, et al., editors. Acetylsalicylic acid in cerebral ischemia and coronary heart disease. Stuttgart: Shattauer, 1978: 97–106

    Google Scholar 

  41. Britton M, Helmers C, Samuelsson K. High-dose acetylsalicylic acid after cerebral infarction: a Swedish co-operative study. Stroke 1987; 18: 325–34

    Article  Google Scholar 

  42. SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345–9

    Article  Google Scholar 

  43. Sorensen PS, Pedersen H,Marquardsen J, et al. Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischaemic attacks: a Danish cooperative study. Stroke 1983; 14: 15–22

    Article  PubMed  CAS  Google Scholar 

  44. Bousser MG, Eschwege E, HaguenauM, et al. AICLA controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14: 5–14

    Article  PubMed  CAS  Google Scholar 

  45. Bousser MG, Eschwege E, Haguenau M, et al. Essai coopératif contrôlé de prévention secondaire des accidents ischémiques cérébraux liés à l’athérosclérose par l’aspirine et le dipyridamole. Presse Med 1983; 12: 3049–57

    PubMed  CAS  Google Scholar 

  46. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. BMJ 1988; 296: 316–20

    Article  Google Scholar 

  47. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044–54

    Article  Google Scholar 

  48. Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel: clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med 1998; 3 (3): 257–60

    PubMed  CAS  Google Scholar 

  49. Dippel DW. The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial. Thromb Res 1998; 92 (1 Suppl. 1): S13–6

    Article  Google Scholar 

  50. SPIRIT study group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin: the Stroke Prevention Reversible Ischemia Trial (SPIRIT) Study. Ann Neurol 1997; 42 (6): 857–65

    Article  Google Scholar 

  51. CARS study group. Randomised double-blind trial of fixed low-dose warfarin with aspirin after MI: Coumadin Aspirin Reinfarction Study (CARS) investigators. Lancet 1997; 350 (9075): 389–96

    Article  Google Scholar 

  52. SPAF III study group. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrilation: stroke prevention in atrial fibrilation III randomised clinical trial. Lancet 1996; 348 (9028): 633–8

    Article  Google Scholar 

  53. Meschengieser SS, Fondevilla CG, Frontroth J, et al. Low-intensity anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 1997; 113 (5): 910–6

    Article  PubMed  CAS  Google Scholar 

  54. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993; 35: 219–26

    Article  PubMed  CAS  Google Scholar 

  55. Ministère des Affaires Sociales, de la Santé et de la Ville. L’échelle nationale des coûts relatifs par Groupe Homogène de Malades 1995. Paris: Ministère des Affaires Sociales, de la Santé et de la Ville, 1996

    Google Scholar 

  56. Lévy E, Le Pen C. Le coût des maladies vasculaires cérébrales non hémorragiques. In: Rancurel G, editor. La prévention des accidents ischémiques cérébraux. Paris: Sanofi Wintrop, 1994: 245–56

    Google Scholar 

  57. Lecomte T. Evolution de la morbidité déclarée. France 1970- 1980. Paris: Centre de Recherche et de Documentation en Economie de la Santé (CREDES), 1986

    Google Scholar 

  58. Castiel D, Herve C, Gaillard M. Devenir socio-professionnel des patients traités pour infarctus du myocarde. Cah Sociol Demogr Med 1991; 31: 167–81

    PubMed  CAS  Google Scholar 

  59. Castiel D, Herve C, Gaillard M, et al. Incidence du niveau de revenu chez des patients atteints d’infarctus du myocarde et thrombolysés. J d’Econ Med 1993; 11: 45–53

    Google Scholar 

  60. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. Working paper 4164. Cambridge (MA): National Bureau of Economic Research, 1992

    Google Scholar 

  61. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16: 1–31

    Article  PubMed  CAS  Google Scholar 

  62. Arnau JM, Agusti A. Is aspirin underused in myocardial infarction? Pharmacoeconomics 1997; 12: 524–32

    Article  PubMed  CAS  Google Scholar 

  63. American Society of Health System Pharmacists. ASHP therapeutic position statement on the use of aspirin for prophylaxis of MI. Am J Health Syst Pharm 1997; 54 (17): 1984–7

    Google Scholar 

  64. Weinstein MC, Manning WG. Theoretical issues in cost-effectiveness analysis. J Health Econ 1997; 16: 121–8

    Article  PubMed  CAS  Google Scholar 

  65. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16: 33–64

    Article  PubMed  CAS  Google Scholar 

  66. Bonneux L, Barendregt JJ, Nusselder WJ, et al. Preventing fatal diseases increases healthcare costs: cause elimination life table approach. BMJ 1998; 316: 26–9

    Article  PubMed  CAS  Google Scholar 

  67. Hoehn JP, Randall A. Too many proposals pass the benefit cost test. Am Econ Rev 1989; 79: 544–51

    Google Scholar 

  68. Birch S, Gafni A. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? J Health Econ 1992; 11: 279–96

    Article  PubMed  CAS  Google Scholar 

  69. Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J Health Econ 1993; 12: 459–67

    Article  PubMed  CAS  Google Scholar 

  70. Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein’s (mis) application of economics to real world problems. J Health Econ 1993; 12: 469–76

    Article  PubMed  CAS  Google Scholar 

  71. Whitford DL, Southern AJ. Audit of secondary prophylaxis after MI. BMJ 1994; 309: 1268–9

    Article  PubMed  CAS  Google Scholar 

  72. Meehan TP, Hennen J, Radford MJ, et al. Process and outcome of care for acute MI among Medicare beneficiaries in Connecticut: a quality improvement demonstration project. Ann Intern Med 1995; 122: 928–36

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study received funding from Sanofi-Synthélabo France.

Author information

Authors and Affiliations

  1. Department of Health Economics, Centre de Recherches Economiques, Sociologiques et de Gestion (CRESGE), Catholic University of Lille, 60 boulevard Vauban, BP 109, F-59016, Lille, France

    Jean-Pierre Marissal, Bernard Selke & Thérèse Lebrun

Authors
  1. Jean-Pierre Marissal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernard Selke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thérèse Lebrun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Pierre Marissal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marissal, JP., Selke, B. & Lebrun, T. Economic Assessment of the Secondary Prevention of Ischaemic Events with Lysine Acetylsalicylate. Pharmacoeconomics 18, 185–200 (2000). https://doi.org/10.2165/00019053-200018020-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200018020-00008

Keywords

Search

Navigation